MAM
Deepak Bhatnagar joins Fruzzanté as director and part of senior management
NEW DELHI: Taking its expansion plans further, Fruzzanté, a part of Hill Zill Winery and a family-owned brand founded by Priyanka Save and Nagesh Pai in 2016, has brought on board Deepak Bhatnagar, as one of the directors of the company.
With more than 30 years of accomplished career history, DB (as he is fondly known) recently retired as the director – sales and marketing at Sula Vineyards. While he still continues his contribution at Sula as an advisor, he has joined hands with his long-time family friend Shrikant Save at Hill Zill Wines. At Fruzzanté, he will focus on product visibility and brand awareness.
DB is a senior sales and marketing management executive and well-known in the industry for delivering revenue and profits within highly competitive markets. A dedicated and reliable leader, he possesses exceptional negotiation skills and problem-solving abilities. In his career span, DB has worked with some well-known brands including Lowenbrau Buttenheim Pvt Ltd, Som Distilleries, Forbes and Cambell, etc.
Fruzzanté co-founder Priyanka Save said, “It is heartening to have DB sir on board as a part of our senior management. He comes with years of extensive experience in the industry and is someone I have also known ina personal capacity for a long time. Our focus for the last few months, ever since the Covid-19 pandemic, has been on a complete overhaul of our offerings in a better and bigger way. From rebranding to Fruzzanté – Sparkling Alcoholic Beverage to extensively using a digital marketing approach, we are leaving no stone unturned. With DB sir on board, we will be able to take this a step ahead.”
Adding further, Deepak Bhatnagar said, “Fruzzanté is a brand to reckon with already in its domain and I am happy to join the team. We have already made some changes to the marketing strategy. The idea is to make use of various marketing and distribution channels for better product visibility as well as brand awareness.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
